Research Summary

William C. Chen, MD, is a Clinical Instructor and post-doctoral fellow in the Department of Radiation Oncology at the University of California, San Francisco. His research interests focus on development and translation of molecular biomarkers for meningioma and other central nervous system (CNS) malignancies, and on understanding the role of chromosomal instability and immune dysregulation in meningioma radiotherapy resistance.

Education

MD, 05/2018 - , University of California, San Francisco
BS, 05/2012 - Biomedical Engineering, Johns Hopkins University

Honors & Awards

  • 2023
    Society for Neuro-Oncology (SNO) Radiation Award
  • 2023
    Radiological Society of North America Roentgen Resident/Fellow Research Award
  • 2023
    Bradley Stuart Beller Endowed Special Merit Award, American Society of Clinical Oncology (ASCO)
  • 2022
    Young Investigator Award, American Society of Clinical Oncology (ASCO)
  • 2022
    Bradley Stuart Beller Endowed Special Merit Award, American Society of Clinical Oncology (ASCO)
  • 2022
    Young Oncologist Travel Grant Award, American Radium Society (ARS)
  • 2021
    Brain Tumor SPORE Developmental Research Grant, UCSF
  • 2021
    Clinical Trials Workshop Scholar, Society of Neuro-Oncology (SNO)
  • 2021
    Clinical and Translational Institute Catalyst Award, UCSF
  • 2021
    Clinical Informatics and Data Science Pathway Program, UCSF
  • 2021
    Clinical and Translational Institute Resident Research Funding Award, UCSF

Selected Publications

  1. Nguyen MP, Morshed RA, Youngblood MW, Perlow HK, Lucas CG, Patel AJ, Palmer JD, Horbinski CM, Magill ST, Chen WC, Raleigh DR. A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence. Neuro Oncol. 2025 Feb 10; 27(2):445-454.  View on PubMed
  2. Leclair NK, Choudury A, Chen WC, Magill ST, McCortney K, Horbinski CM, Chen Z, Goldschmidt E, Eaton CD, Bulsara KR, Bi WL, Patel AJ, Sahm F, Raleigh D, Anczukow O. RNA splicing as a biomarker and phenotypic driver of meningioma DNA-methylation groups. Neuro Oncol. 2024 Dec 05; 26(12):2222-2236.  View on PubMed
  3. Choudhury A, Cady MA, Lucas CG, Najem H, Phillips JJ, Palikuqi B, Zakimi N, Joseph T, Birrueta JO, Chen WC, Oberheim Bush NA, Hervey-Jumper SL, Klein OD, Toedebusch CM, Horbinski CM, Magill ST, Bhaduri A, Perry A, Dickinson PJ, Heimberger AB, Ashworth A, Crouch EE, Raleigh DR. Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy. Cancer Discov. 2024 Oct 04; 14(10):1823-1837.  View on PubMed
  4. Morshed RA, Nguyen MP, Youngblood MW, Perlow HK, Lucas CG, Patel AJ, Palmer JD, Chandler JP, Theodosopoulos PV, Magill ST, Chen WC, Raleigh DR. Gene Expression Changes Associated With Recurrence After Gross Total Resection of Newly Diagnosed World Health Organization Grade 1 Meningioma. Neurosurgery. 2025 Mar 01; 96(3):521-528.  View on PubMed
  5. Nguyen MP, Almiron Bonnin D, Mirchia K, Chen WC, Goldschmidt E, Braunstein SE, Perry A, Raleigh DR, Oberheim Bush NA. Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiency. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae092.  View on PubMed
  6. Thirimanne HN, Almiron-Bonnin D, Nuechterlein N, Arora S, Jensen M, Parada CA, Qiu C, Szulzewsky F, English CW, Chen WC, Sievers P, Nassiri F, Wang JZ, Klisch TJ, Aldape KD, Patel AJ, Cimino PJ, Zadeh G, Sahm F, Raleigh DR, Shendure J, Ferreira M, Holland EC. Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcome. Cell Genom. 2024 Jun 12; 4(6):100566.  View on PubMed
  7. Lucas CG, Mirchia K, Seo K, Najem H, Chen WC, Zakimi N, Foster K, Eaton CD, Cady MA, Choudhury A, Liu SJ, Phillips JJ, Magill ST, Horbinski CM, Solomon DA, Perry A, Vasudevan HN, Heimberger AB, Raleigh DR. Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution. Nat Genet. 2024 Jun; 56(6):1121-1133.  View on PubMed
  8. Raleigh DR, Chen WC, Gondi V, Rogers L, Mehta M. Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice. J Neurooncol. 2024 Aug; 169(1):215-217.  View on PubMed
  9. Liu SJ, Casey-Clyde T, Cho NW, Swinderman J, Pekmezci M, Dougherty MC, Foster K, Chen WC, Villanueva-Meyer JE, Swaney DL, Vasudevan HN, Choudhury A, Pak J, Breshears JD, Lang UE, Eaton CD, Hiam-Galvez KJ, Stevenson E, Chen KH, Lien BV, Wu D, Braunstein SE, Sneed PK, Magill ST, Lim D, McDermott MW, Berger MS, Perry A, Krogan NJ, Hansen MR, Spitzer MH, Gilbert L, Theodosopoulos PV, Raleigh DR. Epigenetic reprogramming shapes the cellular landscape of schwannoma. Nat Commun. 2024 Jan 12; 15(1):476.  View on PubMed
  10. Vasudevan HN, Payne E, Delley CL, John Liu S, Mirchia K, Sale MJ, Lastella S, Nunez MS, Lucas CG, Eaton CD, Casey-Clyde T, Magill ST, Chen WC, Braunstein SE, Perry A, Jacques L, Reddy AT, Pekmezci M, Abate AR, McCormick F, Raleigh DR. Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. Nat Commun. 2024 Jan 12; 15(1):477.  View on PubMed
  11. Raleigh D, Nguyen M, Chen W, Zakimi N, Mirchia K, Lucas CH. Pan-cancer copy number variant analysis identifies optimized size thresholds and co-occurrence models for individualized risk-stratification. Res Sq. 2024 Jan 11.  View on PubMed
  12. Chen WC, Choudhury A, Youngblood MW, Polley MC, Lucas CG, Mirchia K, Maas SLN, Suwala AK, Won M, Bayley JC, Harmanci AS, Harmanci AO, Klisch TJ, Nguyen MP, Vasudevan HN, McCortney K, Yu TJ, Bhave V, Lam TC, Pu JK, Li LF, Leung GK, Chan JW, Perlow HK, Palmer JD, Haberler C, Berghoff AS, Preusser M, Nicolaides TP, Mawrin C, Agnihotri S, Resnick A, Rood BR, Chew J, Young JS, Boreta L, Braunstein SE, Schulte J, Butowski N, Santagata S, Spetzler D, Bush NAO, Villanueva-Meyer JE, Chandler JP, Solomon DA, Rogers CL, Pugh SL, Mehta MP, Sneed PK, Berger MS, Horbinski CM, McDermott MW, Perry A, Bi WL, Patel AJ, Sahm F, Magill ST, Raleigh DR. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 Dec; 29(12):3067-3076.  View on PubMed
  13. Perlow HK, Nalin AP, Handley D, Gokun Y, Blakaj DM, Beyer SJ, Thomas EM, Raval RR, Boulter D, Kleefisch C, Bovi J, Chen WC, Braunstein SE, Raleigh DR, Knisely JPS, Ivanidze J, Palmer JD. A Prospective Registry Study of 68Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial Meningiomas. Int J Radiat Oncol Biol Phys. 2024 Mar 15; 118(4):979-985.  View on PubMed
  14. Vasudevan HN, Delley C, Chen WC, Mirchia K, Pan S, Shukla P, Aabedi AA, Nguyen MP, Morshed RA, Young JS, Boreta L, Fogh SE, Nakamura JL, Theodosopoulos PV, Phillips J, Hervey-Jumper SL, Daras M, Pike L, Aghi MK, Tsai K, Raleigh DR, Braunstein SE, Abate AR. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy. JAMA Netw Open. 2023 08 01; 6(8):e2329186.  View on PubMed
  15. Choudhury A, Cady MA, Lucas CG, Najem H, Phillips JJ, Palikuqi B, Zakimi N, Joseph T, Birrueta JO, Chen WC, Bush NAO, Hervey-Jumper SL, Klein OD, Toedebusch CM, Horbinski CM, Magill ST, Bhaduri A, Perry A, Dickinson PJ, Heimberger AB, Ashworth A, Crouch EE, Raleigh DR. NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy. bioRxiv. 2023 Jul 11.  View on PubMed
  16. Chen WC, Lucas CG, Magill ST, Rogers CL, Raleigh DR. Radiotherapy and radiosurgery for meningiomas. Neurooncol Adv. 2023 May; 5(Suppl 1):i67-i83.  View on PubMed
  17. Lucas CH, Mirchia K, Seo K, Najem H, Chen W, Zakimi N, Choudhury A, Liu SJ, Phillips J, Magill S, Horbinski C, Solomon D, Perry A, Vasudevan H, Heimberger A, Raleigh D. Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution. Res Sq. 2023 May 15.  View on PubMed
  18. Raleigh D, Chen W, Choudhury A, Youngblood M, Polley MY, Lucas CH, Mirchia K, Maas S, Suwala A, Won M, Bayley J, Harmanci A, Harmanci A, Klisch T, Nguyen M, Vasudevan H, McCortney K, Yu T, Bhave V, Lam TC, Pu J, Leung G, Chang J, Perlow H, Palmer J, Haberler C, Berghoff A, Preusser M, Nicolaides T, Mawrin C, Agnihotri S, Resnick A, Rood B, Chew J, Young J, Boreta L, Braunstein S, Schulte J, Butowski N, Santagata S, Spetzler D, Bush NAO, Villanueva-Meyer J, Chandler J, Solomon D, Rogers C, Pugh S, Mehta M, Sneed P, Berger M, Horbinski C, McDermott M, Perry A, Bi W, Patel A, Sahm F, Magill S. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Res Sq. 2023 Mar 20.  View on PubMed
  19. Choudhury A, Chen WC, Lucas CG, Bayley JC, Harmanci AS, Maas SLN, Santagata S, Klisch T, Perry A, Bi WL, Sahm F, Patel AJ, Magill ST, Raleigh DR. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 2023 03 14; 25(3):520-530.  View on PubMed
  20. Khan AB, English CW, Chen WC, Athukuri P, Bayley JC, Brandt VL, Shetty A, Hadley CC, Choudhury A, Lu HC, Harmanci AO, Harmanci AS, Magill ST, Raleigh DR, Klisch TJ, Patel AJ. Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma. Acta Neuropathol. 2023 04; 145(4):501-503.  View on PubMed

Go to UCSF Profiles, powered by CTSI